Vaxart
Highly Engaged Employees
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
310 Utah Ave Ste 150, South San Francisc...Phone Number
(650) 550-3500Website
www.vaxart.comRevenue
$237.3 MillionStock Symbol
VXRTIndustry
About Vaxart
Vaxart Org Chart
Is Vaxart your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Vaxart, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Vaxart is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Vaxart
Click to see if Vaxart had a recent Job posting/layoffs
Check if Vaxart has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Vaxart launches new products
Earning: See what the market has to say on Vaxart recently announced quarterly report
Funding: Get notified immidiatlly once Vaxart has new funding data
Recommended Actions
Reach out to Masked Content who joined Vaxart as Masked Content
Find more new buyers
Compare Similar Companies to Vaxart
Compare insights from companies similar to Vaxart, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vaxart is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vaxart is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vaxart.
Vaxart financials insights
Gather financial insights about Vaxart, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$3.3M
Series B
$16.9M
Stock Offering
$26.9M
Multiple Rounds
$21.3M
Stock Offering
$10M
Debt
$90M
Vaxart Tech Stack
A closer look at the technologies used by Vaxart
Most Recent Scoops
Vaxart News & Media
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel CohortVaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
Urges Stockholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAYVaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in two upcoming events surrounding the BIO International Convention, taking place June 22-25, 2026, at the San Diego Convention Center in San Diego, CA.Vaxart to Participate in BTIG Infectious Disease Day 2026
SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in the BTIG Infectious Disease Day 2026 on June 16.
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vaxart
Vaxart is a biotechnology company focused on developing oral vaccines delivered in pill form to help prevent infectious diseases and improve vaccine accessibility. Using its proprietary delivery platform, the company develops vaccines for conditions such as coronavirus, norovirus, influenza, and human papillomavirus, aiming to provide convenient, n... Read More
